Stay updated with breaking news from Recurrent Stroke. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not reduce recurrent stroke vs aspirin in the ARCADIA trial.
Despite surgical advances, adding extracranial-intracranial bypass to medical therapy does not reduce stroke or death in symptomatic occlusion of the internal carotid or middle cerebral artery.
Clinicians shouldn't expect apixaban to offer benefit over aspirin in patients with embolic stroke of undetermined source simply because they have atrial cardiopathy, ARCADIA investigators conclude.
Cognitive impairment, ranging from mild to severe, is common after a stroke; screening may help detect it early and allow appropriate multidisciplinary care, the AHA says